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A chemical approach for the synthesis of the DNA-binding domain 
of the oncoprotein MYC 
Renata Calo-Lapido,a Cristina Penas,a Adrián Jiménez-Balsa,a M. Eugenio Vázquez,*,a and José L. 
Mascareñas*,a
We describe the first chemical synthesis of a functional mutant of 
the DNA binding domain of the oncoprotein MYC, using two 
alternative strategies which involve either one or two Native 
Chemical Ligations (NCLs). Both routes allowed the efficient 
synthesis of a miniprotein which is capable of heterodimerizing 
with MAX, and replicate the DNA binding of the native protein. 
The versatility of the reported synthetic approach enabled the 
straightforward preparation of MYC and Omomyc analogues, as 
well as fluorescently labeled derivatives. 
The oncogenic MYC transcription factor is a key signaling hub 
that integrates multiple cellular pathways,0 F1  and is deregulated 
and overexpressed in many tumors.1 F2  As a member of the 
basic helix–loop–helix-leucine zipper (bHLH-Zip) family of 
transcription factors,2 F3 MYC effects are mediated by its 
association with other proteins of the same family, and in 
particular with MAX. The resulting MYC/MAX heterodimers are 
capable of binding selectively to E-box sites (CACGTG) of gene 
promoters. Despite its pharmacological interest, targeting MYC 
and affecting its dimerization properties is far from trivial.3F4,4F5
In this context, recent work by the group of L. Soucek has 
shown that a protein analogue, omomyc, interferes with the 
activity of MYC and induces growth arrest.5 F6
 A major drawback for exploring the biological and 
therapeutic properties of these proteins derives from the lack 
of efficient methods for their production. Recombinant 
methods are slow,6F7 and more importantly, they do not easily 
allow the introduction of non-natural elements or purposely 
designed modifications, such as the introduction of small 
fluorophores. In this context, alternative chemical approaches 
are desirable, and they provide practical and versatile 
syntheses of this protein and designed derivatives. 
Herein, we report the total synthesis of a 82-residue 
miniprotein featuring the DNA interacting domain of natural 
MYC, with two specific mutations, Asn500→Ala and 
Asn515→Gln, which do not affect its DNA binding but facilitate 
the synthesis.7F8
The assembly of such long peptide was carried in a convergent 
way by using Native Chemical Ligations (NCL). In its standard 
format, NCL involves the reaction between a C-terminal 
peptide-thioester and and anN-terminal cysteinyl peptide.8F9
Since MYC lacks cysteine residues in its sequence, we chose 
Xaa-Ala as ligation sites because Ala residues can be readily 
obtained by desulfurization of the Cys required for the NCL.9F10
 Preliminary assays of the solid phase assembly of the 
N-terminal peptide fragments revealed the formation of a 
small proportion of undesired products resulting from 
spontaneous deamination of asparagine residues Asn500 and 
Asn515.10F11 Considering that these residues are not involved in 
DNA contacts of the natural protein, or in the formation of the 
MYC/MAX heterodimer, we decided to replace Asn500 by Ala, 
and Asn515 by Gln, so that our final target would be a double 
MYC mutant [AQ]MYC (Figure 1). We designed two 
disconnection schemes using either one or two NCL reactions 
(Figure 1b). The first case requires the synthesis of two long 
peptides corresponding to Ala500–Lys536 (37 residues) and 
Ala537–Leu581 (45 residues) fragments (2Fr-NCL, Figure 1b, left), 
while the second approach involved three shorter peptide 
segments, Ala500–Phe522, Ala523–Thr547, and Ala548–Leu581,
featuring 23, 25 and 34 residues, respectively (3Fr-NCL, Figure 
1b, right). The three-fragment approach is more convergent, 
and hence more appropriate to obtain N-labeled [AQ]MYC 
derivatives. Moreover, we anticipated that the double Cys 
intermediate, [AQ,C523,C548]MYC, obtained in the 3-Fr-NCL 
strategy, might be exploited to implement redox- controlled 
DNA binding.  
Peptides were assembled using the Nbz method,11F12 which 
involves the postsynthetic generation of a C-terminal N-acyl 
urea leaving group (N-acyl-benzimidazolinone, Nbz) by on-
resin modification of a precursor 3,4-diaminobenzoic acid 
(Dbz) with p-nitrophenyl chloroformate (ESI). 
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 After cleavage and deprotection, the Nbz group can be 
readily exchanged with thiol additives at neutral pH to produce 
the peptide thioesters required for the NCL (Figure 1b). Briefly, 
the two-fragment approach allowed the assembly of [AQ]MYC 
using a single NCL by coupling peptide segments A500K536–Nbz 
and C537L581 in the presence of 4-mercaptophenyl acetic acid 
(MPAA) as arylthiol catalyst. The reaction was essentially 
complete after 4.5 h (54 %, 15 mg scale). The desulfurated 
target peptide ([AQ]MYC) was readily obtained [AQ,C537]MYC 
using standard radical-based methods.12F13 Assembly of 
[AQ]MYC following the three-fragment approach (3Fr-NCL) 
was carried out in a similar way. In this case, one of the 
peptide fragments used in the first NCL step features the Cys in 
the form of thiazolidine (Thz) to avoid oligomerization and 
unwanted self-couplings (Thz523T547, Figure 1).13F14  Following the 
first NCL, the Thz was removed by adding hydroxylamine to 
the reaction mixture and adjusting the pH to 4, and the 
resulting peptide (C523Q581) was isolated by HPLC (over 20 % 
for this NCL). The second NCL afforded the expected product 
(in this case containing two Cys residues in positions 548 and 
523), which was isolated by reverse phase HPLC (Figure S18). 
After desulfurization and purification, we obtained [AQ]MYC 
(over 4 % global yield). It must be highlighted that both 
synthetic approaches (2Fr-NCL and 3Fr-NCL) can be carried out 
at a milligram scale to give the desired miniprotein [AQ]MYC, 
which presented a good water solubility.  
 With [AQ]MYC at hand, we studied its DNA binding 
properties in comparison with the wild-type DNA binding 
domain of MYC (wtMYC).14F15  In agreement with earlier reports, 
MAX is capable of binding as homodimer to the E-box site, 
although with a low association constant (Figure 2a and b, 
lanes 2 and 3). In contrast, wtMYC does not appear to dimerize 
and bind to the DNA (Figure 2a, lanes 4 and 5). As expected, 
incubation of MAX with increasing concentrations of wtMYC, 
resulted in the appearance of a slightly less retarded band 
(Figure 2a, lanes 6-9) that is consistent with the formation of 
the DNA complex of the MAX/wtMYC heterodimer.15F16 
Importantly, our synthetic MYC analog, [AQ]MYC, reproduces 
the MAX recognition and DNA binding of wtMYC, although with 
some differences: [AQ]MYC shows a slightly more tendency to 
homodimerize (Figure 2b, lane 5), and the heterodimer of 
[AQ]MYC with MAX binds the target E-DNA at lower 
concentrations than that of wtMYC (Figure 2a and 2b, compare 
lanes 7). Control EMSA experiments with mutated DNAs 
demonstrated that the [AQ]MYC/MAX heterodimer binds the 
E-DNA with high selectivity (Figure S30). Circular Dichroism 
studies were also consistent with the expected binding/folding 
processes (Figure S39).16F17 
 
Figure 1. a) Sequence and structural elements of the DNA binding domain of MYC. b) Alternative disconnection schemes for synthesizing the Asn500→Ala and Asn515→Gln 
MYC mutant ([AQ]MYC) from two (2Fr-NCL, left) or three peptide fragments (3Fr-NCL, right), showing the positions selected for the introduction of the reactive Cys (or Thz) 
residues. NCL conditions: 6 M Gdn HCl, 200 mM phosphate buffer (pH 7.5), 100 mM 4-mercaptophenylacetic acid (MPAA), 40 mM tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP·HCl), 4.5 h; Desulfurization: 6 M Gdn HCl, 200 mM phosphate buffer (pH 7.0), 500 mM TCEP (tris(2-carboxyethyl) phosphine), EtSH,  VA-044 (2-2’-
azobis[2-(2-imidazolin-2-yl) propane]dihydrochloride) 1 M, 37º C, 5 h. 
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Figure 2. Non-denaturing EMSA showing the binding of MAX, the expressed wtMYC, and 
the synthetic [AQ]MYC to a double stranded oligo containing the target E-box 
sequence (E-DNA, 5´-CTGTAGGC CACGTG ACCGGATG-3´, only one chain shown). a) 
Lanes 1-3: 0, 500, and 1000 nM MAX; lanes 5-6: 500 and 1000 nM wtMYC; lanes 7-10: 
250, 500, and 750 nM wtMYC with constant 500 nM MAX. b) same as in gel a, but with 
the synthetic [AQ]MYC instead of wtMYC. All lanes contain 50 nM E-DNA in 20 mM Tris-
HCl pH 7.5, 90 mM KCl, 1.8 mM MgCl2, 1.8 mM EDTA, 9% glycerol, 0.11 mg/mL BSA, 
2.25% NP-40 (20 ºC). The gels were visualized by staining with SYBRTM Gold.  
 These experiments confirm that the synthetic product 
[AQ]MYC heterodimerizes with MAX to bind the E-box site. 
One of the advantages of the synthetic approach is that, in 
addition to the final product [AQ]MYC, we also obtained the 
synthetic intermediate [AQ,C523,C548]MYC, featuring Cys at the 
ligation sites. Inspection of the X-ray structure of the 
cMYC/cMAX/DNA complex reveals that the positions 
corresponding to these cysteine residues are not involved in 
DNA binding (Figure 3a), and therefore we predicted that this 
mutant might show similar DNA binding properties than 
[AQ]MYC. We also reasoned that engaging these cysteines in 
an intramolecular disulfide bond should abolish the DNA 
binding. For simplicity, from now on we will refer to the double 
Cys mutant, [AQ,C523,C548]MYC, as [AQ]MYC(SH). Treatment of 
[AQ]MYC(SH) with DTNB (5,5’-dithiobis-(2-nitrobenzoic acid), 
in 100 mM Tris⋅HCl buffer (pH 7.5) for 1 h,17F18 led to the 
corresponding oxidized peptide [AQ]MYC(S-S), featuring a 
disulfide crosslink between residues Cys523 and Cys548 (isolated 
and identified by ESI-MS, see the ESI). 
 Addition of increasing amounts of [AQ]MYC(SH) to a 
mixture of MAX and E-DNA resulted in two slow-migrating 
bands, the first, predominant at low [AQ]MYC(SH) 
concentrations, must correspond to the homodimeric MAX2/E-
DNA complex, (Figure 3a, lanes 1-4, band a); the second band, 
observed at higher concentrations of [AQ]MYC(SH), is 
consistent with the heterodimeric [AQ]MYC(SH)/MAX/E-DNA 
complex (Figure 3a, band b). As expected, oxidation provides a 
disulfide that is unable to cooperate with MAX and bind DNA, 
and therefore we only observe the band arising from the MAX 
homodimer (Figure 3b, lane 1). However, in situ addition of a 
reducing agent (TCEP) regenerates the parent reduced peptide 
[AQ]MYC(SH), and the heterodimeric DNA binding (Figure 4b, 
lane 2). These preliminary results propose a strategy to 
develop externally activatable MYC surrogates. Using the 
three-fragment NCL we also synthesized the labeled analogs 
TMR-[AQ]MYC(SH) and TMR-[AQ]MYC, featuring a TMR (5-
Carboxytetramethylrhodamine) fluorophore at the N-terminal 
positions (see the ESI). 
 Moreover, following the same three-fragment approach, 
we synthesized two Omomyc analogues: (TMR-
[AQS]OMOMYC and the bis-cysteine derivative (TMR-
[AQS]OMOMYC(SH) (ESI). 18F19  Preliminary uptake studies 
revealed that the cysteine-containing miniproteins are more 
efficiently internalized (over 4 times in A549 and 7-8 times in 
HeLa) than the desulfurized analogues (Figure 4, top vs bottom 
micrographies and Figure S37).19F20,20F21 
 
Figure 3. Top: X-ray structure of the complex MYC-MAX/DNA, highlighting the positions 
of the cysteines in [AQ]MYC(SH) (shown in orange). Middle: Schematic representation 
of the reduction/activation process: The crosslinked [AQ]MYC(S-S) adopts a 
conformation incompatible with MAX binding. Bottom: a) EMSA analysis of the DNA 
binding of [AQ]MYC(SH) and MAX to E-DNA: Lanes 1-4: 50 nM E-DNA; lanes 2-4: 500 
nM MAX and 250, 500, and 1000 nM of [AQ]MYC(SH); b) Redox switching: 50 nM E-
DNA, lane 1: 500 nM MAX and 1000 nM [AQ]MYC(S-S); lane 2: after addition of TECP. 
All lanes contain 50 nM DNA in 20 mM Tris-HCl pH 7.5, 90 mM KCl, 1.8 mM MgCl2, 1.8 
mM EDTA, 9 % glycerol, 0.11 mg/mL BSA, 2.25 % NP-40 (20 ºC). Dashed line indicates 
that the top and bottom of the gel with the bands was mounted in the final image. 
 Additionally, the Omomyc analogue is also better uptaken 
than TMR-[AQ]MYC; and tends to accumulate in the 
perinuclear space (Figure S36). Our results confirm that small 
variations in the sequence of MYC can have very important 
consequences in solubility, aggregation and internalization 
properties. 
 In summary, we have reported the first synthesis of a 
functional, DNA-binding analog of the bHLHzip domain of MYC 
using chemical methods. The flexibility of the methodology 
allowed a practical synthesis of a redox-activatable, and 
fluorescently tagged derivatives not only of MYC but also of its 
therapeutically-relevant analog Omomyc. These derivatives 
could not be assembled using expression approaches. Cell 
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uptake studies revealed that all the miniproteins are 
internalized, albeit with different efficiencies, depending on 
the sequences.  
 
Figure 4. Overlay of both red channel and DIC fluorescence micrographies of A549 cells 
incubated for 4 h with 250 nM of the synthetic peptides in DMEM (without FBS). Cells 
were then washed twice with PSB solution and three more times with DMEM. Pictures 
were taken at 60X and λexc = 561 nm for the red channel, in a confocal microscope. 
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